Pfizer and BioNTech defeat Moderna's COVID-19 vaccine patent claim in an international intellectual property ruling with cross-border licensing implications
Pfizer and BioNTech have defeated a patent infringement claim brought by Moderna relating to COVID-19 vaccine technology. The ruling, reported by Law360, represents a significant outcome in the long-running global battle over mRNA (messenger RNA) vaccine patents — the technology that underpins all three of the major COVID-19 vaccines developed during the pandemic. Moderna had claimed that Pfizer and BioNTech's vaccine infringed its patents covering mRNA modification technology. The case is part of a broader web of international patent litigation between the parties, with actions filed in multiple jurisdictions including the US, UK, Germany, and the Netherlands. A win for Pfizer and BioNTech in any jurisdiction weakens Moderna's overall licensing position and may influence the outcome of parallel cases elsewhere. The cross-border dimension is legally important: patent rights are territorial, meaning a win in one jurisdiction does not automatically bind courts elsewhere, but findings of fact — particularly on issues of novelty and inventive step — can carry persuasive weight in parallel proceedings. No specific court or jurisdiction is named in the available source, nor are any law firm advisers identified.
Why this matters
The mRNA patent dispute between Moderna, Pfizer, and BioNTech is one of the most commercially significant intellectual property (IP) battles of the decade, with billions of dollars in licensing revenue and future vaccine development rights at stake. A ruling in favour of Pfizer and BioNTech removes one strand of Moderna's patent portfolio from the infringement map, reducing its leverage in cross-licensing negotiations globally. For international law firms, the case illustrates the complexity of coordinating multi-jurisdictional patent litigation: separate legal teams must manage local proceedings while aligning on overarching strategy and ensuring consistent factual positions across forums. The outcome will also influence how pharmaceutical companies structure IP licensing arrangements for next-generation mRNA therapeutics.
On the Ground
A trainee supporting an international IP litigation matter of this type would assist with cross-border legal opinion coordination — instructing local counsel in each relevant jurisdiction and consolidating their analysis — and preparing choice-of-law summaries comparing how key patent law concepts (novelty, inventive step, claim construction) are applied across the relevant jurisdictions.
Interview prep
Soundbite
Patent wins are territorial — a Pfizer victory in one forum weakens Moderna's licensing hand globally without ending the war.
Question you might get
“How does the territorial nature of patent rights affect the strategy of a pharmaceutical company pursuing infringement claims in multiple jurisdictions simultaneously?”
Full answer
Pfizer and BioNTech have defeated Moderna's patent claim over COVID-19 vaccine mRNA technology in a ruling that reduces Moderna's infringement case in at least one jurisdiction. This matters because multi-jurisdictional patent litigation of this scale is not resolved by a single verdict — Moderna is pursuing parallel claims in multiple countries, and this outcome, while significant, is one data point in a complex global strategy. The wider picture is that mRNA technology is the platform on which the next generation of vaccines and therapeutics will be built, making control of the underlying IP enormously valuable commercially. Law firms advising biotech and pharma clients on IP strategy will see sustained demand for international patent portfolio management and cross-border litigation coordination as this sector matures.
My notes
saved